Last reviewed · How we verify
DFD-03
DFD-03 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.
DFD-03 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects. Used for Muscle wasting and cachexia, Sarcopenia in aging populations.
At a glance
| Generic name | DFD-03 |
|---|---|
| Also known as | Tazarotene 0.1% Lotion |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Drug class | Selective Androgen Receptor Modulator (SARM) |
| Target | Androgen Receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Musculoskeletal |
| Phase | Phase 3 |
Mechanism of action
DFD-03 selectively activates androgen receptors in muscle and bone tissue, promoting anabolism and muscle growth with reduced activity in prostate and other androgenic tissues. This selective tissue distribution aims to provide the therapeutic benefits of androgens while reducing unwanted androgenic and estrogenic adverse effects associated with traditional hormone therapies.
Approved indications
- Muscle wasting and cachexia
- Sarcopenia in aging populations
Common side effects
- Testosterone suppression
- Liver enzyme elevation
- Headache
- Nausea
Key clinical trials
- A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks (PHASE3)
- A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris (PHASE3)
- A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris (PHASE2)
- A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFD-03 CI brief — competitive landscape report
- DFD-03 updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI